Autoimmune diseases and infections: Controversial issues

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Baio, Pierangelo ^a   Brucato, Antonio ^a   Buskila, Dan ^b   Gershwin, M Eric ^c   Giacomazzi, Donatella ^d   Lopez, Luis R ^e   Luzzati, Roberto ^d   Matsuura, Eiji ^f   Selmi, Carlo ^g   Sarzi Puttini, Piercalo ^h   Atzeni, Fabiola ^h  

^a OSPEDALI RIUNITI   (Italy)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^e Division of Medicine   (United States)

^f OKAYAMA UNIVERSITY   (Japan)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoantibody mediated atherosclerosis in antiphospholipid syndrome; Fibromyalgia; H. pylori infection induced atherosclerosis; Pericarditis; Pericardium; Primary biliary cirrhosis; Pyrexia of unknown origin

Indexed keywords

ANTIBIOTIC AGENT; COLCHICINE; CORTICOSTEROID; LOW DENSITY LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; RUBELLA VACCINE; XENOBIOTIC AGENT; ZIDOVUDINE;

ANTIBIOTIC THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHLAMYDOPHILA PNEUMONIAE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FIBROMYALGIA; GENETIC REGULATION; GRAM NEGATIVE INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEREDITY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERICARDITIS; PORPHYROMONAS GINGIVALIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; VACCINATION; VIRUS VIRULENCE;

AUTOIMMUNE DISEASES; HUMANS; INFECTION;

EID: 42549100897     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. IMAZIO M, TRINCHERO R: Triage and management of acute pericarditis. Int J Cardiol 2007; 118: 286-94.
2. BRUCATO A, BRAMBILLA G, MOREO A et al.: Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol 2006; 98: 267-71.
3. LEVY PY, HABIB G, COLLART F et al.: Etiological diagnosis of pericardial effusion. Future Microbiol 2006; 1: 229-39.
4. MAISH B, SEFEROVIC PM, RISTIC AD et al.: Guidelines on the diagnosis and management of pericardial diseases executive summary; The task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology. Eur Heart J 2004; 25: 587-610.
5. IMAZIO M, CECCHI E, DEMICHELIS B et al.: Indicators for poor prognosis of acute pericarditis. Circulation 2007; 115: 2739-44.
6. LANGE RA, HILLIS DH: Acute pericarditis. N Engl J Med 2004; 351: 2195-202
7. LESLEY J, BURGES S, MED M et al.: The use of Adenosine Deaminase and INF gamma as diagnostic tools for tuberculous pericarditis. Chest 2002; 122: 900-5.
8. SPODICK DH: Infectious pericarditis. In SODICK DH (Ed.) The pericardium: A comprehensive textbook. New York, Marcel Dekker, 1197: 260-90.
9. MAISH B: RecurrentMpericarditis: mysterious or not so mysterious? Eur Heart J 2005; 26: 631-3.
10. BRUCATO A, SHINAR Y, BRAMBILLA G et al.: Idiopathic recurrent acute pericarditis: Familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients. Lupus 2005; 14: 670-4.
11. MATSUURA E, IGARASHI Y, FUJIMOTO M, ICHIKAWA K, KOIKE T: Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
12. MATSUURA E, IGARASHI Y, YASUDA T, TRIPLETT DA, KOIKE T: Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
13. MATSUURA E, KOBAYASHI K, TABUCHI M, LOPEZ LR: Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006; 45: 466-86.
14. HASUNUMA Y, MATSUURA E, MAKITA Z, KATAHIRA T, NISHI S, KOIKE T: Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-73.
15. KOBAYASHI K, MATSUURA E, LIU Q et al.: A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001; 42: 697-709.
16. TABUCHI M, INOUE K, USUI-KATAOKA H et al.: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007; 48: 768-81.
17. KAJIWARA T, YASUDA T, MATSUURA E: Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. J Autoimmun 2007; 29: 164-73.
18. YAMAGUCHI Y, SETA N, KABURAKI J, KOBAYASHI K, MATSUURA E, KUWANA M: Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007; 110: 4312-8.
19. AYADA K, YOKOTA K, KOBAYASHI K, SHOENFELD Y, MATSUURA E, OGUMA K: Chronic infections and atherosclerosis. Ann N Y Acad Sci 2007; 1108: 594-602.
20. OKADA T, AYADA K, USUI S, YOKOTA K et al.: Antibodies against heat shock protein 60 derived from Helicobacter pylori: Diagnostic implications in cardiovascular disease. J Autoimmun 2007; 29: 106-15.
21. AOKI CA, ROIFMAN CM, LIAN ZX et al.: IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006; 27: 50-3.
22. VAN DE WATER J, ISHIBASHI H, COPPEL RL, GERSHWIN ME: Molecular mimicry and primary biliary cirrhosis: Premises not promises. Hepatology 2001; 33: 771-5.
23. GERSHWIN ME, SELMI C, WORMAN HJ et al.: Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology 2005; 42: 1194-202.
24. SELMI C, GERSHWIN ME: BacteTia and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol 2004; 16: 406-10.
25. SELMI C, BALKWILL DL, INVERNIZZI P et al.: Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38: 1250-7.
26. TOUBI E, GORDON S, KESSEL A, ROSNER I et al.: Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: Association with autoimmunity. J Autoimmun 2006; 27: 134-9.
27. SELMI C, ROSS SR, ANSARI AA et al.: Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127: 493-501.
28. RIEGER R, GERSHWIN ME: The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 2007; 28: 76-84.
29. ALLINA J, HU B, SULLIVAN DM, FIEL MI et al.: T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006; 27: 232-41.
30. RIEGER R, LEUNG PS, JEDDELOH MR et al.: Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 2006; 27: 7-16.
31. BUSKILA D, SARZI -PUTTINI P, ABLIN JN: The genetics of fibromyalgia syndrome. Pharmacogenomics 2007; 8: 67-74.
32. ABLIN JN, SHOENFELD Y, BUSKILA D: Fibromyalgia, infection and vaccination: Two more parts in the etiological puzzle. J Autoimmun 2006; 27: 145-52.
33. ADAK B, TEKEOGLU I, EDIZ L et al.: Fibromyalgia frequency in hepatitis B carriers. J Clin Rheumatol 2005, 11: 157-9.
34. RIVERA J, DE DIEGO A, TRINCHET M, GARCIA MONFORTE A: Fibromyalgia associated hepatitis C virus infection. Br J Rheumatol 1997, 36: 981-5.
35. BUSKILA D, SHNAIDER A, NEUMANN L, ZILBERMAN D, HILZENRAT N, SIKULER E: Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arck Interm Med 1997, 157: 2497-500.
36. SIMMS RW, ZERBINI CA, FERRANTE N, ANTHONY J, FELSON DT, CRAVEN DE: Fibromyalgia syndrome in patients infected with human immunodeficiency virus. The Boston City Hospital Clinical AIDS Team. Am J Med 1992, 92: 368-74.
37. BUSKILA D, GLADMAN DD, LANGEVITZ P, UROWITZ S, SMYTHE HA: Fibromyalgia in human immunodeficiency virus infection. J Rheumatol 1990, 17: 1202-6.
38. ABELES AM, PILLINGER MH, SOLITAR BM, ABELES M: Narrative Review: The Pathophysiology of Fibromyalgia. Ann Intern Med 2007, 146: 726-34.
39. WEIBEL RE, BENOR DE: Chronic arthropathy and musculoskeletal symptoms associated with rubella vaccines. A review of 124 claims submitted to the National Vaccine Injury Compensation Program. Arthritis Rheum 1996, 39: 1529-34.
40. HOTOPF M, DAVID A, HULL L, ISMAIL K, UNWIN C, WESSELY S: Role of vaccinations as risk factors for ill health in veterans of the Gulf War: Cross sectional study. BMJ 2000, 320: 1363-7.
41. DURACK DT, STREET AC: Fever of unknown origin - reexamined and redefined. Curr Clin Top Inf Dis 1991; 11: 35-51.
42. KNOCKAERT DC, VANDERSCHUEREN S, BLOCKMANS D: Fever of unknown origin in adults: 40 years on. J Intern Med 2003; 253: 263-75.
43. VANDERSCHUEREN S, KNOCKAERT D, ADRIAENSSENS T et al.: From prolonged febrile illness to fever of unknown origin. Arch Int Med 2003; 163: 1033-41.
44. DE KLEUN EM, VANDENBROUCKE JP, VAN DER MEER JW: Fever of unknown origin (FUO). I. A prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore) 1997; 76: 392-400.
45. KNOCKAERT DC, VANNESTE LJ, BOBBAERS HJ: Recurrent or episodic fever of unknown origin. Review of 45 cases and survey of the literature. Medicine (Baltimore) 1993; 72: 184-96.
46. KALYONCU M; ACAR BC; CAKAR N et al: Are carriers for MEFV mutations "healthy"? Clin Exp Rheumatol 2006; 24: S120-2.
47. GÜL A: Selective pressures for the high prevalence of MEFV variants induced by small-pox infection in the "Old World": A hypothesis. Clin Exp Rheumatol 2006; 24: 213.
48. KNOCKAERT DC, DUJARDIN KS, BOBBAERS HJ: Lon-term follow-up of patients with undiagnosed fever of unknown origin. Arch Int Med 1996; 156: 618-20.
49. BLEEKER-ROVERS CP, VOS FJ, DE KLEIJN EM et al.: A prospective multicenter study on fever of unknown origin. Medicine 2007; 86: 26-38.
50. SALTOGLU N, TASOVA Y, MIDIKLI D et al.: Fever of unknown origin in Turkey: Evaluation of 87 cases during a nine-year-period of study. J Infect 2004; 48: 81-5.
51. AUZARY C; LE THI RUONG D, DELARBREX X et al.: Subacute bacterial endocarditis presenting as polymyalgia rheumatica or giant cell arteritis. Clin Exp Rheumatol 2006; 24: S38-40.
52. KNOKAERT DC, VANNESTE U, BOBBAERS HJ: Fever of unknown origin in the elderly patients. J Am Geriatric Soc 1993; 41:1187-92.
53. F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32: 191-6.